Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +48.68%
#3 DOVU DOVU +48.00%
#4 Velvet Velvet +44.04%
#5 Black Phoenix Black Phoenix +34.47%
#6 Ο„emplar Ο„emplar +19.02%
#7 Cross Cross +18.07%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.92%
#9 Perle Perle +16.73%
#10 Ribbita by Virtuals Ribbita by Virtuals +15.85%
Coin of the day
Glidr Glidr
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Kedudukan dalam Saham #38382
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Harga Saham
$0.02468497
Modal Pasaran
$1.01M
Perubahan (1 hari)
-12.50%
Perubahan (1 tahun)
-87.34%
Negara
AU
Perdagangan Chimeric Therapeutics Limited (CHM)

Kategori

Healthcare
Hasil untuk Chimeric Therapeutics Limited (CHM)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Chimeric Therapeutics Limited, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Chimeric Therapeutics Limited dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE